Ypsomed Divests Pen Needle: Focuses on Insulin Pump Innovation

إبسوماد تسحب إبرة القلم: تركز على ابتكار مضخة الأنسولين

الخميس، مارس 28 مارس 2024

تقوم شركة Ypsomed بتحويل أعمال إبرة القلم ومضخة الأنسولين إلى شركة MTD، وتوجيه الاستثمار في توسيع موقع سولوتورن وتعزيز حلول مضخة الأنسولين.

Ypsomed, a notable player in the healthcare sector, has divested its pen needle and glucose monitoring systems (BGMs) segment to Medical Technology and Devices S.p.A. (MTD) وفقًا لبيان صحفي.

This decision is aligned with Ypsomed’s vision to concentrate on advancing and commercialising its cutting-edge mylife Loop insulin pump solution. The transition to MTD, anticipated to finalise in summer 2024, is set to ensure a continuous supply of high-quality pen needles, catering to the global demand from insulin and hormone injectors.

In the interim, Ypsomed will continue manufacturing pen needles under a contract arrangement, facilitating a smooth transition by mid-2025. This business segment, now transitioning to MTD, recorded sales of over CHF 50 million in the fiscal year 2022/23, with a subsequent CHF 18 million in the first half of FY 2023/24.

MTD aims to enrich its portfolio with Ypsomed’s acclaimed click technology and its own 34G pen needle, envisioning expanded market reach and enhanced service to the diabetes community.

Ypsomed is set to channel over CHF 100 million into its Solothurn site over the next four years, boosting autoinjector production capabilities. This expansion will not only augment its manufacturing capacity but also introduce a new injection moulding tool shop, thereby creating numerous job opportunities.

Ypsomed assures its workforce of continued employment and is actively seeking avenues to accommodate all employees affected by the business transition within the group or through partner recruiting agencies.

قصص ذات صلة

Commerzbank Quarterly Earnings Surge

15 مايو 2024

Commerzbank announces a pre-tax profit of nearly €1.1 billion for Q1, marking its best quarterly performance in over...

Swiss Running Shoe Brand On: Record Breaking Quarter

14 مايو 2024

On Running's turnover exceeds CHF 500 million in Q1 2024, with sales up 21% and net profit more than doubling. Positive...

Swiss Re Exceeds Expectations with Strong Q1

16 مايو 2024

Swiss Re kicks off 2024 with impressive Q1 earnings of $1.09 billion, outpacing estimates thanks to a strong investment...

University Of Geneva Want To Prosecute Students: More Palestine Protests

14 مايو 2024

Swiss universities experience protests demanding academic boycotts of Israeli institutions and the removal of Israeli...

Alcon, Swiss Pharmaceutical Firm Growth Slows

14 مايو 2024

Alcon sees a 5% increase in Q1 sales, achieving $2.44 billion with profits surging to $248 million, despite a minor...

Esprit Files For Insolvency In Europe

16 مايو 2024

Esprit takes a significant step towards restructuring by entering insolvency for its parent and several subsidiaries in...

Foreign Minister Cassis Meets With The European Council

14 مايو 2024

At the Council of Europe's meeting in Strasbourg, discussions will center on Ukraine support and AI regulation, marking...

ابق على اتصال

جدير بالملاحظة

Switzerland To Pay The EU: ‘Cohesion Fund’

جدير بالملاحظة

6 مايو 2024

Switzerland To Pay The EU: ‘Cohesion Fund’

Logitech’s Start to the Year: Mixed Reviews

جدير بالملاحظة

30 أبريل 2024

إبسوماد تسحب إبرة القلم: تركز على ابتكار مضخة الأنسولين

إبسوماد تسحب إبرة القلم: تركز على ابتكار مضخة الأنسولين

قصص ذات صلة

ابق على اتصال

جدير بالملاحظة

Switzerland To Pay The EU: ‘Cohesion Fund’

بداية العام من لوجيتك: مراجعات متباينة

روابط سريعة